AnaptysBio, Inc.
ANABNASDAQHealthcare● Active
$51.36
+$0.99(+1.97%)
Market Cap$2.2B
P/E Ratio—
52W High$72.36
52W Low$11.404
AnaptysBio, Inc. (ANAB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANAB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$1.84
Est. -$0.32 · -475.0%
Revenue
$0.03B
Est. $0.02B · +35.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
ANAB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.05 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.32 | -$1.84 | -475.0% | $0.03B | $0.02B | +35.5% |
| ▲ Q1 FY2026 | Mar 3, 2026 | $0.89 | $1.58 | +77.5% | $0.11B | $0.09B | +24.4% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$1.06 | $0.52 | +149.1% | $0.08B | $0.02B | +248.2% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$1.50 | -$1.34 | +10.7% | $0.02B | $0.01B | +90.5% |
| ▲ Q2 FY2025 | May 5, 2025 | -$1.30 | -$1.28 | +1.5% | $0.03B | $0.02B | +81.8% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$1.55 | -$0.72 | +53.5% | $0.04B | $0.01B | +453.9% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$1.72 | -$1.14 | +33.7% | $0.03B | $0.01B | +265.8% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$1.84
EPS Est.
-$0.32
EPS Surpr.
-475.0%
Revenue
$0.03B
Q1 FY2026
Mar 3, 2026Beat
EPS Actual
$1.58
EPS Est.
$0.89
EPS Surpr.
+77.5%
Revenue
$0.11B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.52
EPS Est.
-$1.06
EPS Surpr.
+149.1%
Revenue
$0.08B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$1.34
EPS Est.
-$1.50
EPS Surpr.
+10.7%
Revenue
$0.02B
Q2 FY2025
May 5, 2025Beat
EPS Actual
-$1.28
EPS Est.
-$1.30
EPS Surpr.
+1.5%
Revenue
$0.03B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.72
EPS Est.
-$1.55
EPS Surpr.
+53.5%
Revenue
$0.04B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$1.14
EPS Est.
-$1.72
EPS Surpr.
+33.7%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.27 | $1.27 | $1.27 | 2 |
| Q3 FY2027 | $0.32 | $0.32 | $0.32 | 1 |
| Q2 FY2027 | $0.07 | $0.07 | $0.07 | 1 |
| Q1 FY2027 | $-0.06 | $-0.06 | $-0.06 | 2 |
| Q4 FY2026 | $-0.50 | $-0.50 | $-0.50 | 2 |
| Q3 FY2026 | $-0.89 | $-0.23 | $0.11 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -475.0% | $67.92 | $65.58 | -3.45% |
| ▲ Q1 FY2026 | Mar 3, 2026 | +77.5% | $36.61 | $35.22 | -3.80% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +149.1% | $24.03 | $23.16 | -3.62% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +10.7% | $15.03 | $13.58 | -9.65% |
| ▲ Q2 FY2025 | May 5, 2025 | +1.5% | $14.13 | $13.82 | -2.19% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +53.5% | $11.33 | $10.93 | -3.53% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +33.7% | $13.29 | $13.25 | -0.30% |
| ▼ Q3 FY2024 | Aug 5, 2024 | -42.5% | $21.84 | $21.58 | -1.19% |
Q2 FY2026-3.45%
Report Date
May 12, 2026
EPS Beat/Miss
-475.0%
Price Before
$67.92
Price After
$65.58
Q1 FY2026-3.80%
Report Date
Mar 3, 2026
EPS Beat/Miss
+77.5%
Price Before
$36.61
Price After
$35.22
Q4 FY2025-3.62%
Report Date
Nov 4, 2025
EPS Beat/Miss
+149.1%
Price Before
$24.03
Price After
$23.16
Q3 FY2025-9.65%
Report Date
Aug 7, 2025
EPS Beat/Miss
+10.7%
Price Before
$15.03
Price After
$13.58
Q2 FY2025-2.19%
Report Date
May 5, 2025
EPS Beat/Miss
+1.5%
Price Before
$14.13
Price After
$13.82
Q1 FY2025-3.53%
Report Date
Feb 27, 2025
EPS Beat/Miss
+53.5%
Price Before
$11.33
Price After
$10.93
Q4 FY2024-0.30%
Report Date
Nov 5, 2024
EPS Beat/Miss
+33.7%
Price Before
$13.29
Price After
$13.25
Q3 FY2024-1.19%
Report Date
Aug 5, 2024
EPS Beat/Miss
-42.5%
Price Before
$21.84
Price After
$21.58
Avg Beat Reaction-3.85%
Avg Miss Reaction-2.32%
Beat Rate6 / 8 quarters
Largest Move-9.65% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANAB ends December
AnaptysBio, Inc. (ANAB) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-1.84 — missing the analyst consensus of $-0.32 by -475.0%. The next ANAB earnings date is expected around September 1, 2026.
Each quarter, investors track ANAB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANAB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANAB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANAB earnings · 5 questionsAnaptysBio, Inc.'s next earnings report is expected around September 1, 2026. ANAB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANAB historically reports after market close (AMC).
ANAB earnings datewhen is ANAB earningsANAB next earnings datewhen does ANAB report earningsANAB earnings calendar
▸ Source: FMP · AnaptysBio, Inc. SEC filings · US GAAP · AnaptysBio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026